

line 21, before "153" insert --SEQ ID NO:129--, before "209" insert --SEQ ID NO:156--;

line 22, before "154" insert --SEQ ID NO:130--, before "210" insert --SEQ ID NO:157--;

line 23, before "155" insert --SEQ ID NO:131--, before "211" insert --SEQ ID NO:158--;

line 24, before "156" insert --SEQ ID NO:132--, before "212" insert --SEQ ID NO:159--;

line 25, before "157" insert --SEQ ID NO:133--, before "213" insert --SEQ ID NO:160--;

line 26, before "158" insert --SEQ ID NO:134--, before "214" insert --SEQ ID NO:161--;

line 27, before "159" insert --SEQ ID NO:135--, before "215" insert --SEQ ID NO:162--.

Page 73, line 3, replace "17" with --29--, replace "18" with --30--, replace "19" with --31-- and replace "20" with --32--;
line 7, after "146" insert --SEQ ID NO:123--.

Please delete the Sequence Listing originally filed with the application, appearing on pages 76-87, and renumber the pages sequentially thereafter.

Please amend the claims as follows:

2. A vaccine according to claim 1, wherein the nucleotide sequence is selected from SEQ ID NO. [9] 18 or SEQ ID NO. [10] 19.
3. A vaccine according to claim 1, wherein the homologue has at least 80% sequence identity to SEQ ID NO. [9] 15 or SEQ ID NO. [10] 19.
4. A vaccine according to claim 1, wherein the nucleotide sequence is selected from SEQ ID NO. [11] 23 or SEQ ID NO. [12] 25.

5. A vaccine according to claim 1, wherein the homologue has at least 80% sequence identity to SEQ ID NO. [11] 23 or SEQ ID NO. [12] 25.
6. A vaccine according to claim 4, wherein the nucleotide sequence is SEQ ID NO. [12] 25.
8. A vaccine according to claim 7, wherein the homologue has at least 80% sequence identity to SEQ ID NO. [9] 15 or SEQ ID NO. [10] 19.
9. A vaccine according to claim 7, wherein the nucleotide sequence is selected from SEQ ID NO. [11] 23 or SEQ ID NO. [12] 25, or a homologue or fragment thereof.
10. A vaccine according to claim 9, wherein the homologue has at least 80% sequence identity to SEQ ID NO. [11] 23 or SEQ ID NO. [12] 25.
11. A vaccine according to claim 9, wherein the nucleotide sequence is SEQ ID NO. [12] 25.
12. A vaccine according to claim 7, wherein the polypeptide has the amino acid sequence of SEQ ID NO. [14] 24 or SEQ ID NO. [15] 26.
13. A vaccine according to claim 7, wherein the polypeptide has the amino acid sequence of SEQ ID NO. [15] 26.
14. A vaccine according to claim 7, wherein the homologue has at least 80% sequence identity to SEQ ID NO. [14] 24 or SEQ ID NO. [15] 26.
15. A vaccine according to claim 7, wherein the homologue has at least 80% sequence identity to SEQ ID NO. [15] 26.
16. A vaccine according to claim 7, wherein the polypeptide has the amino acid sequence of SEQ ID NO. [17] 29, SEQ ID NO. [18] 30, SEQ ID NO. [19] 31, or SEQ ID NO. [20] 32.
21. A vaccine comprising a pharmaceutically acceptable vehicle and a single polypeptide, wherein the single polypeptide consists of SEQ ID NO. [15] 26.

Please insert the Sequence Listing filed herewith, pages 1-108, after the last page of the application and renumber the pages sequentially.

Respectfully submitted,

Aug. 24, 2000
Date

Patricia D. Granados
Patricia D. Granados
Reg. No. 33,683

FOLEY & LARDNER
3000 K Street, N.W.
Suite 500
Washington, D.C. 20007-5109
202/672-5300